钙网蛋白
免疫原性细胞死亡
黑色素瘤
癌症研究
未折叠蛋白反应
激酶
程序性细胞死亡
综合应力响应
癌细胞
生物
细胞生物学
癌症
细胞凋亡
医学
内科学
内质网
信使核糖核酸
基因
翻译(生物学)
生物化学
作者
Paola Giglio,Mara Gagliardi,Nicola Tumino,Fernanda Antunes,Soraya S. Smaili,Diego Cotella,Claudio Santoro,Roberta Bernardini,Maurizio Mattei,Mauro Piacentini,Marco Corazzari
出处
期刊:OncoImmunology
[Informa]
日期:2018-05-02
卷期号:7 (8): e1466765-e1466765
被引量:61
标识
DOI:10.1080/2162402x.2018.1466765
摘要
The immunogenic cell death (ICD) process represents a novel therapeutic approach to treat tumours, in which cytotoxic compounds promote both cancer cell death and the emission of damage-associated molecular patterns (DAMPs) from dying cells, to activate the immune system against the malignancy. Therefore, we explored the possibility to stimulate the key molecular players with a pivotal role in the execution of the ICD program in melanoma cells. To this aim, we used the pro-ICD agents mitoxantrone and doxorubicin and found that both agents could induce cell death and stimulate the release/exposure of the strictly required DAMPs in melanoma cells: i) calreticulin (CRT) exposure on the cell membrane; ii) ATP secretion; iii) type I IFNs gene up-regulation and iv) HMGB1 secretion, highlighting no interference by oncogenic BRAF. Importantly, although the ER stress-related PERK activation has been linked to CRT externalization, through the phosphorylation of eIF2α, we found that this stress pathway together with PERK were not involved in melanoma cells. Notably, we identified PKR and GCN2 as key mediators of eIF2α phosphorylation, facilitating the translocation of CTR on melanoma cells surface, under pro-ICD drugs stimulation. Therefore, our data indicate that pro-ICD drugs are able to stimulate the production/release of DAMPs in melanoma cells at least in vitro, indicating in this approach a potential new valuable therapeutic strategy to treat human skin melanoma malignancy.
科研通智能强力驱动
Strongly Powered by AbleSci AI